Wave Life Sciences Ltd. — Director's Dealing 2026

Feb 11, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2026-02-05

Reporting Person: Moran Kyle (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-05	Ordinary Shares	A	45625	$0.00	Acquired	137973	Direct
2026-02-09	Ordinary Shares	S	3588	$13.45	Disposed	134385	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-05	Share Option (right to buy)	$12.75	A	273750	Acquired	2036-02-05	Ordinary Shares (273750)	Direct

Footnotes

F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.

F2: Includes 1,983 ordinary shares acquired on January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan.

F3: On February 9, 2026, the reporting person sold 3,588 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.

F4: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.